Mer­ck hands Swedish biotech €10M cash to de­vel­op an­ti-in­flam­ma­to­ry drugs

Mer­ck is bet­ting on Aqil­ion’s work on a small mol­e­cule in­hibitor for au­toim­mune and in­flam­ma­to­ry dis­eases, in­clud­ing neu­ro­log­i­cal dis­eases.

Mer­ck is pay­ing €10 mil­lion up­front …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER